Programmed death‐ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer

Immune checkpoint inhibitor therapy has been clinically introduced for several malignancies, and its effectiveness has been confirmed by clinical trials. In particular, programmed cell death protein 1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) are widely known as important immune checkpoint molecu...

Descripción completa

Detalles Bibliográficos
Autores principales: Amatatsu, Masahiko, Arigami, Takaaki, Uenosono, Yoshikazu, Yanagita, Shigehiro, Uchikado, Yasuto, Kijima, Yuko, Kurahara, Hiroshi, Kita, Yoshiaki, Mori, Shinichiro, Sasaki, Ken, Omoto, Itaru, Maemura, Kosei, Ishigami, Sumiya, Natsugoe, Shoji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834808/
https://www.ncbi.nlm.nih.gov/pubmed/29345842
http://dx.doi.org/10.1111/cas.13508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834808/
https://www.ncbi.nlm.nih.gov/pubmed/29345842
http://dx.doi.org/10.1111/cas.13508

Ejemplares similares